Julia, a mother of three reflects on PMOS/PCOS, fertility treatment, and the overlooked long-term health risks women need to know about.

Wiebke Arlt discusses how identifying distinct PMOS/PCOS subgroups could unlock more personalised treatment and better metabolic-risk prediction.

In this short video, Thomas Faustmann of Gedeon Richter shares an industry perspective on what is needed to move from symptom management towards disease-modifying therapies for PMOS/PCOS.

In this video, Colby Holtshouse from May Health breaks down a critical reality: there is currently no single holistic solution for Polycystic Ovary Syndrome, a condition affecting 1 in 10 women of reproductive age.

Despite affecting millions of women worldwide, PCOS still has no approved therapies specifically for the condition — leaving many patients managing symptoms without targeted treatment. In this short video, Alpha Lee, CSO and Co-Founder of PostEra, explains how PostEra is approaching this challenge.

This report outlines the current challenges and new opportunities in PCOS drug development. Join the conversation on how we can catalyze collaborative efforts to accelerate the development of evidence-based, mechanism-driven therapies that improve outcomes and quality of life for women living with PCOS.